PeerVoice Clinical Pharmacology Audio PeerVoice

Visit https://www.peervoice.com/QQG860 to view the entire programme with slides. After completing “James F. Howard Jr, MD - Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors”, participants will be able to:

Visit https://www.peervoice.com/SZV860 to view the entire programme with slides. After completing “Julia Rotow, MD / Javier Cortés, MD - HER3-Targeted Therapies: How Might These Benefit Our Patients?”, participants will be able to: Recall the molecular and pathological mechanisms of HER3 that make it a promising therapeutic target in non-small cell lung cancer (NSCLC) and breast cancer; and Assess the clinical relevance of safety and efficacy data from randomised clinical trials evaluating HER3-targeted agents.

Visit https://www.peervoice.com/TUZ860 to view the entire programme with slides. After completing “George L. Bakris, MD, MA - Step-by-Step: Setting a Course for Managing CKD and T2DM With Nonsteroidal MRAs”, participants will be able to: Describe the role of nonsteroidal mineralocorticoid receptor antagonists (MRAs) as part of an overall treatment strategy to improve renal and cardiovascular outcomes for patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM); Outline the emerging standards of care for management of patients with CKD and T2DM, based on the “four-pillar” approach; Explain the rationale for the recent updates in management guidelines for patients with CKD and T2DM; and Apply clinical evidence and recommendations to practice in the management of patients with CKD and T2DM, highlighting the role of nonsteroidal MRAs.

Visit https://www.peervoice.com/RKE860 to view the entire programme with slides. After completing “Stefano Fanti, MD - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses”, participants will be able to: Summarise the most recent clinical data for radioligand therapy (RLT) for the management of men with metastatic castration-resistant prostate cancer (mCRPC); Evaluate how these data add to previous knowledge about the management of mCRPC with RLT; and Discuss the clinical implications of these data in the context of current treatment paradigms for mCRPC.

Visit https://www.peervoice.com/JCT860 to view the entire programme with slides. After completing “Kevin Harrington, PhD, FRCR, FRCP - When CPS is Between 1 and 19, How Would You Manage Recurrent/Metastatic SCCHN?”, participants will be able to: Summarise the current treatment guidelines and the importance of combined positive score (CPS) when evaluating first-line systemic treatment options for patients with recurrent/metastatic squamous cell carcinoma of head and neck (SCCHN); Discuss clinical data that help inform treatment plans in patients with recurrent/metastatic SCCHN; and In patients with CPS between 1 and 19, identify patient and disease characteristics that would differentiate patient suitability for a non-immune checkpoint inhibitor (ICI)-based therapeutic regimen versus an ICI-based regimen.

Visit https://www.peervoice.com/ADW860 to view the entire programme with slides. After completing “Nizar Mahlaoui, MD, MPH, PhD - Simplifying Patient-Integrated Care for Those Requiring Immunoglobulin Therapy: Making Smart Moves with Automated and Digital Technology”, participants will be able to: Recognise the impact of the overall administrative burden of subcutaneous immunoglobulin (SCIg) therapy on the patient; Identify technologies that are in development to support patient-integrated care for those requiring SCIg therapy; and Describe how automated and digital devices in development could help streamline the administrative processes and enhance clinical care of patients who require SCIg therapy in the future.